Abstract:Vaccines are one of the most effective strategies to prevent pathogen-induced illness in humans. The earliest vaccines were based on live inoculations with low doses of live or related pathogens, which carried a relatively high risk of developing the disease they were meant to prevent. The introduction of attenuated and killed pathogens as vaccines dramatically reduced these risks; however, attenuated live vaccines still carry a risk of reversion to a pathogenic strain capable of causing disease. This risk is completely eliminated with recombinant protein or subunit vaccines, which are atoxic and non-infectious. However, these vaccines require adjuvants and often significant optimization to induce robust T-cell responses and long-lasting immune memory. Some pathogens produce protein toxins that cause or contribute to disease. To protect against the effects of such toxins, chemically inactivated toxoid vaccines have been found to be effective. Toxoid vaccines are successfully used today at a global scale to protect against tetanus and diphtheria. Recent developments for toxoid vaccines are investigating the possibilities of utilizing recombinant protein toxins mutated to eliminate biologic activity instead of chemically inactivated toxins. Finally, one of the most contemporary approaches toward vaccine design utilizes messenger RNA (mRNA) as a vaccine candidate. This approach was used globally to protect against coronavirus disease during the COVID-19 pandemic that began in 2019, due to its advantages of quick production and scale-up, and effectiveness in eliciting a neutralizing antibody response. Nonetheless, mRNA vaccines require specialized storage and transport conditions, posing challenges for low- and middle-income countries. Among multiple available technologies for vaccine design and formulation, which technology is most appropriate? This review focuses on the considerable developments that have been made in utilizing diverse vaccine technologies with a focus on vaccines targeting bacterial toxins. We describe how advancements in vaccine technology, combined with a deeper understanding of pathogen-host interactions, offer exciting and promising avenues for the development of new and improved vaccines.

Biomaterials, biological molecules, and polymers in developing vaccines

Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications

Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines

Biomaterials as vaccine adjuvants

Biomaterials and nanomaterials for sustained release vaccine delivery

Biological Nanoparticles in Vaccine Development

Biomaterial vaccines capturing pathogen-associated molecular patterns protect against bacterial infections and septic shock

Targeting dendritic cells with biomaterials: developing the next generation of vaccines

Tailoring biomaterials for vaccine delivery

Multifaceted therapeutic applications of biomimetic nanovaccines

Design of nanomaterial based systems for novel vaccine development

Advanced technologies for the development of infectious disease vaccines

Advanced Materials for the Delivery of Vaccines for Infectious Diseases

Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities

Considerations for Size, Surface Charge, Polymer Degradation, Co‐Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases

Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery

Integrating plant molecular farming and materials research for next-generation vaccines

Designing spatial and temporal control of vaccine responses

Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials

Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines

Biomaterial-enhanced cancer vaccines